Improving care for advanced bladder cancer
BCCMA: Translational research to improve the care of advanced bladder cancer
['FUNDING_OTHER'] · BIRMINGHAM VA MEDICAL CENTER · NIH-11098531
This study is looking for better ways to treat advanced bladder cancer by improving current treatments like chemotherapy and immunotherapy, so patients can have a better chance of recovery and a better quality of life, especially for those who may need surgery.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BIRMINGHAM VA MEDICAL CENTER (nih funded) |
| Locations | 1 site (BIRMINGHAM, UNITED STATES) |
| Trial ID | NIH-11098531 on ClinicalTrials.gov |
What this research studies
This research aims to enhance treatment outcomes for patients with advanced bladder cancer by optimizing existing therapies, including chemotherapy, immunotherapy, and targeted therapy. The collaborative effort involves three specialized research teams that will explore innovative approaches, such as using non-toxic oral compounds to combat chemoresistance and developing a new immunotherapy platform. By integrating expertise from basic science to clinical applications, the project seeks to improve both prognosis and quality of life for patients. The research will also investigate how these optimized therapies can enhance surgical outcomes for patients undergoing radical cystectomy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with advanced bladder cancer who are seeking new treatment options.
Not a fit: Patients with early-stage bladder cancer or those who are not diagnosed with bladder cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved quality of life for patients with advanced bladder cancer.
How similar studies have performed: Previous research has shown promise in optimizing cancer therapies, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
BIRMINGHAM, UNITED STATES
- BIRMINGHAM VA MEDICAL CENTER — BIRMINGHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: FERGUSON, JAMES E — BIRMINGHAM VA MEDICAL CENTER
- Study coordinator: FERGUSON, JAMES E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy